Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)wmm2021-02-26T19:14:49+00:00February 18th, 2016|2016 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientificwmm2021-02-26T19:15:19+00:00February 9th, 2016|2016 プレスリリース, プレスリリース| 続きを読む
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutationswmm2021-02-26T19:16:48+00:00December 5th, 2015|Archived プレスリリース, プレスリリース| 続きを読む
